Fkbp52 targeting agent pharmaceutical compositions
US-2016030369-A1 · Feb 4, 2016 · US
FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
US10434075B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10434075-B2 |
| Application number | US-201715623775-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 15, 2017 |
| Priority date | Jun 15, 2016 |
| Publication date | Oct 8, 2019 |
| Grant date | Oct 8, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A therapeutic method comprising administering to a postmenopausal subject having estrogen receptor positive (ER+) and androgen receptor positive (AR+) breast cancer a therapeutically effective amount of enzalutamide and a compound having a chemical structure of Formula I 2. The method of claim 1 , wherein the androgen receptor to estrogen receptor ratio in the breast cancer cells is greater than 2. 3. The method of claim 1 , wherein the subject has been treated or is being treated with aromatase inhibitor therapy. 4. The method of claim 3 , further comprising administering an effective amount of anti-estrogen to the subject. 5. The method of claim 4 , wherein the anti-estrogen is tamoxifen or fulvestrant. 6. The method of claim 1 , further comprising administering chemotherapy or radiation treatments.
Assignees
Inventors
Classifications
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title
1,2,4-Triazoles · CPC title
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
having an oxo group in position 17, e.g. androsterone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10434075B2 cover?
- Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
- Who is the assignee on this patent?
- Cox Marc B, Richer Jennifer, Univ Texas, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/167. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).